source
- Rising costs leave 9 in 10 new medicines unprofitable, IQVIA findsTo achieve a positive return, drugs launched from 2016 to 2020 must generate nearly $12 billion in sales, up from just $1.4 billion for drugs launched in the early 1990s.BioSpace · 1h ago↗ source
- Aclaris scratches TSLP program from pipeline after flunking phase 2 eczema testA phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.Fierce Biotech · 6h ago↗ source
- FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entryThe U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…